N-[2-（3-吡啶基）-6-（1,2,4,5-四氢-3H-3-苯并ze庚因-3-基）-4-嘧啶基]-β-丙氨酸二盐酸盐 | 1394854-52-4

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: N-[2-（3-吡啶基）-6-（1,2,4,5-四氢-3H-3-苯并ze庚因-3-基）-4-嘧啶基]-β-丙氨酸二盐酸盐
• 中文别名: GSKJ2(锂盐)；N-[2-(3-吡啶基)-6-(1,2,4,5-四氢-3H-3-苯并氮杂卓-3-基)-4-嘧啶基]-BETA-丙氨酸
• 英文名称: 3-[[2-(3-Pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid
• 英文别名: 3-[[2-pyridin-3-yl-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidin-4-yl]amino]propanoic acid
• CAS: 1394854-52-4
• 化学式: C₂₂H₂₃N₅O₂
• 分子量: 389.4
• InChiKey: LJIFOCRGDDQFJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  91.2
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• TARGETED THERANOSTICS
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20140227297A1

  公开（公告）日：2014-08-14

  Provided herein is technology relating to theranostic agents and particularly, but not exclusively, to compositions comprising cell-specific theranostic agents and associated methods and systems for using the cell-specific theranostic agents to treat subjects.

  本文提供了与治疗诊断剂有关的技术，特别是但不限于包含特定细胞治疗诊断剂的组合物，以及利用这些特定细胞治疗诊断剂治疗受试者的相关方法和系统。
• Methods for production of functional beta cells
  申请人：Janssen Biotech, Inc.

  公开号：US10633635B2

  公开（公告）日：2020-04-28

  The invention provides for methods of differentiating pancreatic endocrine cells into pancreatic beta cells expressing PDX1, NKX6.1, MAFA, UCN3 and SLC2A. These pancreatic beta cells may be obtained by step-wise differentiation of pluripotent stem cells. The pancreatic beta cells exhibit glucose-dependent mitochondrial respiration and glucose-stimulated insulin secretion similar to islet cells.

  本发明提供了将胰腺内分泌细胞分化成表达PDX1、NKX6.1、MAFA、UCN3和SLC2A的胰腺β细胞的方法。这些胰腺β细胞可通过多能干细胞的逐步分化获得。胰岛β细胞表现出与胰岛细胞相似的葡萄糖依赖性线粒体呼吸和葡萄糖刺激的胰岛素分泌。
• PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS
  申请人：HealOr Ltd.

  公开号：US20140227243A1

  公开（公告）日：2014-08-14

  The present disclosure relates to compositions and methods for accelerating the healing process of wounds, increasing the closure of skin wounds, and decreasing inflammation at the site of a skin wound. Specifically, the disclosure relates to compositions comprising a delta-PKC activator, an alpha-PKC inhibitor, and a pharmaceutically acceptable carrier that is free of Ca 2+ and Mg 2+ cations. The disclosure also relates to compositions comprising an insulin or insulin analog and a pharmaceutically acceptable carrier that is free of Ca 2+ and Mg 2+ cations.
• GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE
  申请人：Janssen Biotech, Inc.

  公开号：US20170362572A1

  公开（公告）日：2017-12-21

  The invention provides for methods of differentiating pancreatic endocrine cells into pancreatic beta cells expressing PDX1, NKX6.1, MAFA, UCN3 and SLC2A. These pancreatic beta cells may be obtained by step-wise differentiation of pluripotent stem cells. The pancreatic beta cells exhibit glucose-dependent mitochondrial respiration and glucose-stimulated insulin secretion similar to islet cells.
• TREATMENT OF DIABETES AND ASSOCIATED METABOLIC CONDITIONS WITH EPIGENETIC MODULATORS
  申请人：Temple Otorongo LLC

  公开号：US20190374525A1

  公开（公告）日：2019-12-12

  The present invention describes small molecules that have the activity of directly enhancing insulin sensitivity through epigenetic regulation. These small molecules, therefore, provide a new path for the treatment of type 2 diabetes and insulin resistance in type 1 diabetes or prediabetes and also can be used to treat obesity and chronic liver disease. Methods and compositions including these small molecules or for their administration are described. The methods and compositions can include additional anti-diabetic agents.